共 50 条
Behcet's disease
被引:0
|作者:
Saadoun, D.
[1
,2
,3
,4
]
机构:
[1] Hop La Pitie Salpetriere, Dept Med Interne & Immunol Clin, 83,Blvd Hop, F-75013 Paris, France
[2] INSERM, UMR S 959, F-75013 Paris, France
[3] CNRS, FRE3632, F-75005 Paris, France
[4] RHU IMAP, Paris, France
来源:
关键词:
Vasculitis;
Behcet's disease;
Biotherapiesa;
VENOUS THROMBOSIS;
MORTALITY;
D O I:
10.1016/j.revmed.2023.10.116
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Behcet's disease (BD) is a systemic large-vessel vasculitis characterized by a wide clinical spectrum including recurrent oral and genital ulcerations, uveitis, vascular, neurological, articular, and gastrointestinal manifestations. Therapeutic management of BD depends of the clinical presentation and organ involved. Although colchicine, nonsteroidal antiinflammatory agents and topical treatments with corticosteroidsare often sufficient for mucocutaneous and joint involvement, a more aggressive approach with immunosuppressive agents is warranted for severe manifestations such as posterior uveitis, retinal vasculitis, vascular, neurological and gastrointestinal involvement. However, some patients still have refractory disease, relapses, sight threatening eye disease, or irreversible organ damage. Recent improvements in the understanding of the pathogenic mechanisms have led to the identification of potential targets and future therapies for BD. In contrast to current non-specific immunosuppressive agents, the emergenceof immunomodulatory drugs provides the possibility of interfering with specific pathogenic pathways. Novel targeted immunosuppressive therapies might be used in the future for BD.
引用
收藏
页码:A299 / A301
页数:3
相关论文